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Abstract
Purpose: Radiographic lung changes after stereotactic body radiation therapy (SBRT) vary widely
between patients. Standardized descriptions of acute (≤6 months after treatment) and late (>6 months
after treatment) benign lung changes have been proposed but the reliable application of these clas-
sification systems has not been demonstrated. Herein, we examine the interobserver reliability of
classifying acute and late lung changes after SBRT.
Methods and materials: A total of 280 follow-up computed tomography scans at 3, 6, and 12 months
post-treatment were analyzed in 100 patients undergoing thoracic SBRT. Standardized descrip-
tions of acute lung changes (3- and 6-month scans) include diffuse consolidation, patchy consolidation
and ground glass opacity (GGO), diffuse GGO, patchy GGO, and no change. Late lung change
classifications (12-month scans) include modified conventional pattern, mass-like pattern, scar-
like pattern, and no change. Five physicians scored the images independently in a blinded fashion.
Fleiss’ kappa scores quantified the interobserver agreement.
Results: The Kappa scores were 0.30 at 3 months, 0.20 at 6 months, and 0.25 at 12 months. The
proportion of patients in each category at 3 and 6 months was as follows: Diffuse consolidation
11% and 21%; patchy consolidation and GGO 15% and 28%; diffuse GGO 10% and 11%; patchy
GGO 15% and 15%; and no change 49% and 25%, respectively. The percentage of patients in each
category at 12 months was as follows: Modified conventional 46%; mass-like 16%; scar-like 26%;
and no change 12%. Uniform scoring between the observers occurred in 26, 8, and 14 cases at 3,
6, and 12 months, respectively.
Conclusions: Interobserver reliability scores indicate a fair agreement to classify radiographic lung
changes after SBRT. Qualitative descriptions are insufficient to categorize these findings because
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most patient scans do not fit clearly into a single classification. Categorization at 6 months may be
the most difficult because late and acute lung changes can arise at that time.
© 2018 The Author(s). Published by Elsevier Inc. on behalf of the American Society for
Radiation Oncology. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Stereotactic body radiation therapy (SBRT) for early stage
lung cancer is the standard of care for medically inoper-
able patients.1 The local control rates are excellent2-4 and
thoracic SBRT has found widespread application in recent
years.5 Post-treatment surveillance primarily consists of serial
computed tomography (CT) scans. The accurate categori-
zation and interpretation of post-SBRT radiographic change
serves numerous purposes: Facilitation of communica-
tion between physicians, correlation between lung
parenchyma changes and development of radiation-induced
toxicity, and identification of tumor recurrence versus benign
change.
Radiographic lung changes after SBRT vary widely
between patients and can vary across different areas of the
lung within individual patients, which makes the classifi-
cation of post-treatment changes difficult. Pneumonitis after
SBRT occurs in 11% to 20% of patients,6-9 and early iden-
tification of high-risk patients may enable an early
intervention to mitigate clinical toxicity.10 In addition, benign
inflammatory and fibrotic lung parenchyma changes can
appear similar to or mask residual or recurrent disease.
The differentiation of a wide range of benign post-
SBRT lung changes from local recurrence is essential to
allow early salvage therapy. However, because local re-
currence is rare (5%-20% of cases),4 aggressive work up
of concerning imaging findings exposes many patients to
unnecessary worry and procedural risks in this com-
monly multi-morbid population (ie, pneumothorax with
repeat biopsies or complications from surgical
interventions).11,12 Methods to identify high-risk features on
follow up CT scans have been proposed13 but approxi-
mately 1 quarter of patients with benign post-treatment lung
changes would be miscategorized using this method.14
Indeed, no consensus exists to manage post-SBRT pa-
tients with suspicious lung changes.15,16 Physician comfort
with evaluating post-treatment imaging is critical because
other accessory information such as beam arrangement,
isodose distribution, and underlying patient characteris-
tics can influence the interpretation of surveillance imaging.
To assist physicians with the evaluation of and facili-
tate interprovider communication with regard to post-
treatment scans, standardized descriptions of acute (<6
months of treatment) and late (>6 months after treatment)
benign lung changes have been proposed (Table 1).17-20 These
descriptions offer guidance to identify and categorize benign
radiographic change but the reliable application of these
classification systems has not been demonstrated. Prior
studies have examined the interobserver agreement of
grading late lung changes after SBRT21,22 but to date, no
study has evaluated the degree of interobserver reliability
in the evaluation of acute lung changes after SBRT. Herein,
we examine the interobserver reliability in the classifica-
tion of acute and late lung changes after SBRT.
Methods and materials
Patient population
The study included 100 patients who underwent tho-
racic SBRT between 2007 and 2016. After approval by our
institutional review board, patients’ radiographic images were
Table 1 Standardized post-treatment radiographic lung change descriptions
Change categories Definitions17-20
Acute (3 and 6 months)
• Diffuse consolidation Consolidation ≥5 cm; involved region contains more consolidation than aerated lung
• Patchy consolidation and GGO Consolidation <5 cm and/or involved region with less consolidation than aerated lung
• Diffuse GGO ≥5 cm GGO; involved region with more GGO than aerated lung
• Patchy GGO <5 cm GGO and/or involved region with less GGO than aerated lung
• No change No new abnormalities or no change larger than the original tumor
Late (12 months)
• Modified conventional pattern Consolidation, volume loss, and bronchiectasis similar to but less extensive than conventional fibrosis
• Mass-like pattern Focal consolidation limited around the original tumor
• Scar-like pattern Linear opacity in the tumor regional with associated volume loss
• No change No new abnormalities or no change larger than the original tumor
GGO, ground glass opacity.
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extracted from the medical records to create a database for
analysis.
At our institution, the target volume was delineated using
the maximal intensity projection images from a
4-dimensional, non-contrast, enhanced CT scan or images
that were obtained with the patient in the breath-hold po-
sition. A 3 mm to 5 mm expansion was used to create the
planning target volume. The most commonly prescribed frac-
tionation regimen was 48 Gy in 4 fractions although other
regimens with similar biologically equivalent doses were
also used. A summary of the patient characteristics is listed
in Table 2.
Imaging data
After SBRT, follow-up CT scans of the thorax were per-
formed every 3 to 6 months. Deep-inspiration breath-
hold scans that were completed 3, 6, and 12 months after
treatment were included in the analysis. For patients simu-
lated for free-breathing treatment, the 30% phase (mid-
ventilation) image of the 4-dimensional treatment planning
scan served as the baseline scan against which follow-up
scans were compared to classify changes in lung paren-
chyma (Fig 1). Planning contours and plan isodose lines
were available to reviewers.
Lung change scoring
The standardized lung change descriptions for acute and
late changes are listed in Table 1. The 5 physician observ-
ers who all had experience in lung SBRT and the
interpretation of post-SBRT follow-up imaging were pro-
vided with explanations of the lung change descriptions with
example images on the basis of prior publications.17,19,23 Sub-
sequently, the reviewers examined de-identified patient scans
Table 2 Patient characteristics (n = 100)
Characteristic Median (Range)
or percent present
Age, y 67 (45-91)
Female sex 54%
African-American race 52%
Stage I 86%
Planning target volume size, cc 24.4 (4.6-187.7)
Fractionation
- 48 Gy in 4 fractions 78%
- 40-60 Gy in 5 fractions 17%
- Other 5%
Forced expiratory volume in 1 second, La 1.32 (0.57-3.07)
Percent predicted diffusing capacity of
the lung for carbon monoxideb
37 (1-130)
a A total of 80 patients with available data.
b A total of 66 patients with available data.
Figure 1 Examples of post-treatment radiographic lung changes. Reviewer scores (frequency) listed by patient. Follow-up scans per-
formed at 3, 6, and 12 months after stereotactic body radiation therapy. Reviewer scores (frequency). Patient A: Uniform observations
of no change at 3 months; diffuse consolidation (2) versus patchy consolidation and ground glass opacity (GGO) (1) versus patchy
GGO (2) at 6 months; modified conventional pattern (4) versus scar-like pattern (1) at 12 months. Patient B: Diffuse GGO (1) versus
no change (4) at 3 and 6 months; scar-like pattern (1) versus no change (4) at 12 months. Patient C: Diffuse consolidation (1) versus
patchy consolidation and GGO (2) versus diffuse GGO (2) at 3 months; patchy consolidation and GGO (3) versus diffuse GGO (2) at
6 months (Of note: shape of radiographic change consistent with mass- or scar-like pattern, a late description); modified conventional
pattern (1) versus mass-like pattern (3) versus scar-like pattern (1) at 12 months.
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with blinding between the reviewers. Commercial soft-
ware (MIM Maestro v6.6, MIM Software, Cleveland, OH)
presented default lung and mediastinal contrast windows
for the scans.
The baseline scans with tumor contours, beam direc-
tions, and isodose distributions were available to the
reviewers. Axial, coronal, and sagittal views were evaluable
for the baseline and follow-up scans. The reviewers scored
patients’ 3-, 6-, and 12-month scans (comparison between
different time points was allowed) and completed the scoring
of all scans prior to examining the next patient. The patient
order was identical between reviewers to assist in evalua-
tion for a training effect. Observers used acute lung change
descriptions for the 3- and 6-month scans and the 12-
month scans were graded using late lung change
descriptions.
Statistical analysis
The reviewer ratings of the acute and late lung change
descriptions were tabulated and summary percentages that
reported the number of times a classification was used by
the 5 observers, divided by the total number of reviews
across all scans and patients at a given time point. Fleiss’
Kappa scores were employed to quantify interobserver
agreement at the 3-, 6-, and 12-month time points. Fleiss’
Kappa is a statistical measure to assess the reliability of
interobserver agreement for nominal data in which there
are ≥2 observers.
The Fleiss’ Kappa is the ratio of achieved interobserver
agreement and possible interobserver agreement. Values of
0 and 1 represent no agreement above that expected by
chance and complete agreement, respectively.24 Leave-one-
out analyses tested for the variability between the observers
and the impact of single observers on the calculated scores.
The assessments of the interobserver agreement for the first
and last 20 patients were performed to evaluate for a po-
tential effect of increasing experience with using the
classification system.
Results
Lung change scoring
In 100 patients undergoing thoracic SBRT, 280 follow-
up CT scans at 3, 6, and 12 months post-treatment were
analyzed. All patients had evaluable 3- and 6-month scans
and 80 patients had 12-month scans. The patient charac-
teristics are provided in Table 2.
With regard to acute lung changes, the most frequently
used classification at 3 months was no change (49%), fol-
lowed by patchy consolidation and ground glass opacity
(GGO) and patchy GGO (both 15%). At 6 months, patchy
consolidation and GGO (28%) surpassed the no-change clas-
sification (25%) as the most common, followed by diffuse
consolidation (21%; Table 3). The reported percentages rep-
resent the number of times a classification was used, divided
by the total number of scores across all patients in a given
follow-up period. Uniform scoring among the 5 observ-
ers occurred in 26 patients at 3 months and 8 patients at 6
months. In scans with uniform scoring, no change was the
most common description (85%).
At 12 months, modified conventional pattern was the
most commonly graded late lung change (46%), followed
by scar-like pattern (26%) and mass-like pattern (16%;
Table 3). Uniform scoring among the 5 raters occurred in
14 cases (18%). Modified conventional pattern was the most
common description (79%) in cases with uniform rating.
Interobserver reliability
The 3- and 6-month Fleiss’ Kappa scores were 0.30 and
0.20, respectively. Leave-one-out analyses demonstrated
similar mean Kappa scores of 0.30 (standard deviation [SD]:
0.02) and 0.19 (SD: 0.04), respectively. Interobserver re-
liability improved with experience at both time points and
increased from 0.20 to 0.29 between the first and last 20
patients at 3 months and from 0.03 to 0.25 at 6 months
(Table 4).
Table 3 Frequency of radiographic lung change classifications
Follow-up time Diffuse
consolidation
Patchy consolidation
and GGO
Diffuse
GGO
Patchy
GGO
No
change
3 monthsa 11% 15% 10% 15% 49%
6 monthsa 21% 28% 11% 15% 25%
Follow-up time Modified
conventional
Mass-like
pattern
Scar-like
pattern
No
change
12 monthsb 46% 16% 26% 12%
GGO, ground glass opacity.
All images were reviewed by 5 observers. The percentages present the breakdown of category use across all image reviews at a given time point.
a A total of 100 patients with 498 image reviews.
b A total of 80 patients with 398 image reviews.
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At 12 months, the Fleiss’ Kappa score was 0.25. The
leave-one-out analysis had an identical score (SD: 0.03).
Interobserver agreement decreased between the first and last
20 patients with Kappa scores of 0.25 and 0.16, respec-
tively (Table 4).
Discussion
Thoracic SBRT, which was once used only in selected
medically inoperable patients, has increased in accep-
tance in both frail and fit patients.3,5 This has increased the
importance of detecting radiation-induced lung injury and
accurately differentiating between tumor recurrence and
benign post-treatment changes. Radiation oncologists, with
the benefit of knowing beam arrangements and isodose dis-
tributions, are well suited to evaluate post-treatment images
along with radiologists. However, the interpretation of sur-
veillance imaging is problematic. Despite often dramatic
radiographic lung changes post-treatment, the identifica-
tion of radiographic changes associated with clinical toxicity
and/or local treatment failure remains difficult.14-16,25,26 Ra-
diation oncologists and radiologists need to be familiar with
typical post-SBRT lung changes and their evolution over
time.
To characterize common post-treatment changes for cor-
relation with toxicity and tumor control outcomes as well
as facilitate communication between physicians, specific
classifications of benign acute and late post-treatment
changes have been proposed.17-20,23 However, the consis-
tency of these scoring systems has not been demonstrated.
The purpose of our analysis was to evaluate interobserver
agreement with regard to these categories of benign changes.
This report represents the first study to examine the
interobserver reliability of scoring acute lung changes in
serial scans, which could provide the earliest indication of
tumor response or relapse and patient toxicity.
Our findings show that changes in follow-up scans
become more common and evolved over time. At 3 months,
no change was seen in the plurality of cases and the ma-
jority of cases in which uniform scoring occurred. A lack
of effect is easier to determine relative to assigning a de-
scription of change so the greatest agreement would be
expected in these cases. However, the longer the follow up,
the greater the incidence of radiographic changes became.
Although no change was observed in 49% of the 3-month
scans, this was observed in only 25% of the 6-month scans
and 12% of 12-month scans. The decrease in the number
of patients with no change is consistent with findings of
other studies.21,22 At 12 months, the modified conven-
tional pattern classification became the most common, which
is again consistent with prior studies.21
The interpretation of Kappa scores, which assess
interreviewer reliability above what is expected by chance,
can be categorized as poor (0-0.20), fair (0.20-0.40), mod-
erate (0.40-0.60), strong (0.60-0.80), and almost perfect
(0.80-1) interobserver agreement.27 Kappa scores ranged
from 0.20 to 0.30, which is consistent with a fair degree
of agreement. These scores are lower than those seen in
studies that scored other lung conditions such as intersti-
tial lung diseases (0.30-0.77).28,29 Although increased
category numbers and fewer reviewer and case numbers all
decrease Kappa scores, these factors did not differ greatly
between the cited studies and our study, which indicates
a decreased interobserver agreement in our study.
This lack of reliability likely reflects the high degree of
overlap between the change descriptions and the qualita-
tive nature of the scoring. Nonetheless, our findings are
consistent with a similar study of 77 patients and 6 re-
viewers who evaluated reliability of late (6-48 months) post-
SBRT lung change classifications that reported Kappa scores
that ranged from 0.17 to 0.34.21 Another study with 8 re-
viewers produced similar results with a different measure
of interobserver agreement using the same 77 patient
cohort.22 Leave-one-out analyses did not identify an outlier
observer in the group of raters with the extent of devia-
tion inversely proportional to the overall Kappa scores at
the 3 time points.
Our findings demonstrate that interobserver variability
peaked at 6 months with no dominant lung change de-
scription that emerged (Fig 1). This time point after SBRT
could represent the greatest heterogeneity in patient re-
sponse. Classically, radiation pneumonitis develops 2 to
6 months after SBRT.6-9,30 At 6 months, some patients likely
remain in the acute inflammatory phase of lung reaction
while some have developed patterns of fibrosis that are
typical of late changes. This could make lung changes at
this time point extremely difficult to categorize or require
the option of using late lung change descriptions if deemed
appropriate. Faruqi et al.21 reported a Kappa score of 0.34
using late change descriptions to categorize 6-month scans.
Allowing the use of both acute and late change categories
for 6-month scans may enable better interobserver
agreement in the future. Despite that changes at 6 months
have the highest interobserver variability, raters at this time
point also showed the greatest training effect and the Kappa
score for the final 20 patients equaled the Kappa score
for the grading of the 12-month lung changes. Given
that this time point appeared to give raters the most
trouble, the training effect reasonably would be the stron-
gest here.
Table 4 Interobserver reliability of lung change classifications
Follow-up
time
Kappa
score
Mean Kappa score
(leave-one-out
analysis [SD])
Kappa score
(first/last
20 patients)
3 months 0.30 0.30 (0.02) 0.20/0.29
6 months 0.20 0.19 (0.04) 0.03/0.25
12 months 0.25 0.25 (0.03) 0.25/0.16
SD, standard deviation.
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The training effect was seen for early lung changes and
consistent with that of other studies.21 However, an inverse
effect was observed for 12-month changes and interobserver
agreement worsened with time. Leave-one-out analyses did
not identify an outlier observer in the group. Possibly, the
final scans at 12 months were especially difficult to evalu-
ate. This warrants further evaluation in future studies.
Limitations
The qualitative nature of the lung change descriptions
make interobserver reliability difficult to demonstrate. With
more patients, an increased number of observers, and more
rater experience, interobserver agreement could have been
improved. Longer follow-up times beyond 12 months also
would have allowed for a better characterization of the evo-
lution of late lung changes. Using either acute or late change
categories at a given time point may allow for more reli-
able classifications, especially at 6 months when the
agreement was the lowest.
Alternatively, simplifying the ratings into categories such
as no/minimal change, change concerning for local recur-
rence, and change not concerning for local recurrence could
improve interobserver reliability and clinical utility. Moving
forward, objective measures of lung change such as the
Hounsfield Unit threshold-based delineation of hazy and
dense lung parenchyma changes,31 dose-density response
curves,32 texture features, and/or other radiomic
assessments33,34 may offer a better alternative to catego-
rize lung changes than qualitative descriptions.
Conclusions
Interobserver reliability scores indicate a fair agree-
ment for acute and early late lung change classifications
after SBRT. Qualitative descriptions of post-SBRT radio-
graphic lung changes are insufficient to categorize these
findings because most patient scans do not fit clearly into
a single classification. At 6 months post-SBRT, variabil-
ity in lung changes is the greatest and most difficult to
reliably categorize and patients exhibit both acute and late
lung changes at that time point. Objective measures of ra-
diographic lung changes or a combination of objective and
qualitative measures may offer a better alternative to cat-
egorize these changes.
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